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Gene and Protein Sequence Optimization for High-Level Production
of Fully Active and Aglycosylated Lysostaphin in Pichia pastoris
Hongliang Zhao,a,e Kristina Blazanovic,a Yoonjoo Choi,b Chris Bailey-Kellogg,b Karl E. Griswolda,c,d
Thayer School of Engineering,a Department of Computer Science,b Program in Molecular and Cellular Biology,c and Department of Biological Sciences,d Dartmouth,
Hanover, New Hampshire, USA; Laboratory of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, People’s Republic of Chinae
Lysostaphin represents a promising therapeutic agent for the treatment of staphylococcal infections, in particular those of meth-
icillin-resistant Staphylococcus aureus (MRSA). However, conventional expression systems for the enzyme suffer from various
limitations, and there remains a need for an efficient and cost-effective production process to facilitate clinical translation and
the development of nonmedical applications. While Pichia pastoris is widely used for high-level production of recombinant pro-
teins, there are twomajor barriers to the production of lysostaphin in this industrially relevant host: lack of expression from the
wild-type lysostaphin gene and aberrant glycosylation of the wild-type protein sequence. The first barrier can be overcome with
a synthetic gene incorporating improved codon usage and balanced AT/GC content, and the second barrier can be overcome
by disrupting an N-linked glycosylation sequon using a broadened choice of mutations that yield aglyscosylated and fully active
lysostaphin. The optimized lysostaphin variants could be produced at approximately 500 mg/liter in a small-scale bioreactor,
and 50% of that material could be recovered at high purity with a simple 2-step purification. It is anticipated that this novel high-
level expression system will bring down one of the major barriers to future development of biomedical, veterinary, and research
applications of lysostaphin and its engineered variants.
Lysostaphin (LST) is a glycyl-glycine zinc-dependent endopep-tidase natively encoded on the pACK1 plasmid of Staphylococ-
cus simulans (1), an environmental competitor of Staphylococcus
aureus. LST is synthesized as a preproenzyme of 493 amino acids,
and its pre- (36 amino acids) and pro- (211 amino acids) se-
quences are removed during and after secretion, respectively.Ma-
ture LST is a monomer composed of an N-terminal catalytic do-
main (132 amino acids), a C-terminal cell wall binding domain
(102 amino acids), and a short connecting linker (13 amino acids)
between the two (2). The LST enzyme selectively and efficiently
degrades pentaglycine cross-links in the peptidoglycan compo-
nent of S. aureus cell walls, ultimately resulting in bacterial lysis
and death. Lysostaphin was discovered in the 1960s (3) and has
since undergone various degrees of preclinical development and
even small-scale clinical testing by different groups and organiza-
tions (4–8). Early interest in LST as a therapeutic agent waned as a
result of ready access to conventional drugs, such as methicillin,
but enthusiasm for LST in biomedical applications has been re-
vived due to wide-spread antibiotic resistance and shallow anti-
microbial development pipelines (9).
One barrier to LST clinical applications is the high doses re-
quired to eradicate some infections. LST appeared to show good
efficacy in an unresponsive leukemia patient suffering from mul-
tidrug-resistant staphylococcal pneumonia, multiple abscesses,
and cellulitis (7), but this effect required a 500-mg systemic
bolus of enzyme. In another study, nasal carriers of coagulase-
positive S. aureus were shown to be effectively cleared of the
pathogen following intranasal LST treatment, but this effect re-
quired 2 weeks of 4-times-daily intranasal administration of a 5
mg/ml LST solution (8). Similar results at similar dosages were
obtained in other human studies of nasal carriage clearance (10,
11). In a murine model of catheter-associated S. aureus biofilms,
systemic LST administration was shown to clear established bio-
films during a 4-day treatment regime, and a single prophylactic
dose prevented subsequent biofilm formation on indwelling cath-
eters (12). Extrapolating the effective doses to a human patient,
however, would require asmuch as 16 ormore grams of enzyme to
be administered over 4 days. Thus, while LST has demonstrated
consistent efficacy in animal models and even human studies,
translating the effective dosages to wide-spread clinical use will
require a particularly efficient production platform.
Toward this end, LST has been produced in a wide range of
microbial expression hosts. One source of commercial LST is
high-cell-density cultures of the native organism S. simulans, but
the industrial-scale production yields from this system are with-
held as proprietary information. Alternatively, expression yields
from the bacterial host Escherichia coli are known to range from10
to 20 mg/liter (13–15), and this recombinant platform is also a
significant contributor to commercially sourced material. Large-
scale LST production for clinical trials has been pursued with the
Lactococcus lactisnisin-induced controlled expression (NICE) sys-
tem (16, 17). Expression levels of 100 mg/liter were achieved in
large-volume, high-cell-density fermentations, but the final puri-
fied yields were only 40mg/liter (16). Subsequent process optimi-
zation of this system increased bioreactor expression levels to 300
mg/liter (17), but there remains considerable room for further
improvement. Finally, it bears noting that LST has also been ex-
pressed in mammalian cells (18), but no effort was made toward
maximizing or even quantifying yields.
Pichia pastoris has proved to be a highly successful heterolo-
gous expression host in recent years, withmore than 1,000 recom-
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binant proteins expressed as of 2009 (19). Unlike the aforemen-
tioned prokaryotic systems, P. pastoris has dedicated, high-
capacity protein secretion pathways, which greatly simplify both
upstream and downstream protein purification (20). Moreover,
as a yeast, P. pastoris produces no endotoxins, obviating the need
for arduous and inefficient endotoxin removal steps prior to bio-
medical applications (21). Although P. pastoris is an attractive
recombinant host, the expression of bacterial proteins in these
eukaryotic cells can present its own challenges. In this study, two
key barriers to high-level LST expression in P. pastoris were en-
countered, (i) lack of detectable expression from the wild-type
(WT) LST gene and (ii) aberrant glycosylation at one of two in-
ternal N-linked consensus sequons. These limitations were ad-
dressed by optimizing the gene sequence and the protein se-
quence, respectively.
MATERIALS AND METHODS
Regents and media. Primers with standard desalting were ordered from
IDT Technologies (Coralville, IA). Enzymes for molecular cloning were
purchased fromNew England BioLabs (Ipswich, MA), as was Remove-iT
PNGase F. Commercial LST produced in E. coli was purchased from
Sigma (St. Louis, MO). All other reagents and supplies were from VWR
Scientific (Philadelphia, PA), unless specifically noted.
Plasmids and strains. P. pastoris expression vector pPIC9 and P. pas-
toris strain GS115 were purchased from Invitrogen (Grand Island,
NY). S. aureus strain SA113 was from the American Type Culture Collec-
tion (Manassas, VA). Clinical isolates of S. aureus (strains 6445, 3425-1,
and 3425-3) were the kind gift of Ambrose Cheung (Dartmouth, Hano-
ver, NH).
Design of a synthetic lysostaphin gene (SYN lst). An artificial gene
encoding the wild-type LST enzymewas synthesized to satisfy two general
objectives: (i) to substitute codons satisfying the preferred codon usage of
P. pastoris for wild-type codons and (ii) to balance the AT/GC distri-
bution of segments with disproportionate AT content. In the synthetic
gene, the majority of codons were replaced by the most preferred codons
of P. pastoris (22). However, to disrupt long stretches of AT bases, the
second-most-frequent P. pastoris Thr and Val codons were inserted as
needed. Specifically, ACC (14.5% usage) instead of ACT (22.4% usage)
was occasionally used for Thr, and GTC (14.9%) instead of GTT (26.9%)
was used for Val.
Cloning of lst genes.TheWT lst gene was amplified from S. simulans
with primers WT-F and WT-R (Table 1). The SYN lst gene was synthe-
sized by Shanghai Xuguan Biotechnology Development Company
(Shanghai, China) and amplified with primers SYN-F and SYN-R (Table
1). The chimeric and aglycosylated lst genes were constructed by splice
overlap extension PCR using the primers listed in Table 1. Briefly, paired
5= and 3= fragments of the WT or SYN lst genes were first amplified using
one external primer and one internal primer each, and the resulting frag-
ments were then spliced together in an overlap reaction using external
primers. For example, two fragments for the N125Q pointmutant (with a
change of N to Q at position 125) were generated by amplifying SYN lst
with (i) SYN-F andN125Q-R and (ii) SYN-R andN125Q-F. The resulting
PCRproducts were thenmixed at an equimolar ratio, and themixturewas
used as the template in a subsequent splicing overlap reaction using prim-
ers SYN-F and SYN-R. All PCRs were performed using Phusion high-
fidelity DNA polymerase. The LST-encoding genes were digested with
XhoI and EcoRI, ligated into similarly digested pPIC9, and transformed
by electroporation into E. coliDH5 [F 80lacZM15 (lacZYA-argF)
U169 recA1 endA1 hsdR17 (rK
 mK
) phoA supE44  thi-1 gyrA96
relA1]. This fuses LST in frame with the alphamating factor (MF) secre-
tion signal from Saccharomyces cerevisiae. Clones bearing the expression
vector with the insert were selected by PCR using external primers (either
WT-F with WT-R or SYN-F with SYN-R) and confirmed by DNA se-
quencing.
P. pastoris expression. The pPIC9 expression vectors harboring se-
quenced lst genes were digested with SacI prior to electroporation into P.
pastoris strain GS115. P. pastoris transformants were initially grown on
solid MD medium (1.34% yeast nitrogen base [YNB], 0.00004% biotin,
2% dextrose, 1% agar), then cultured in BMGY medium (1.0% yeast
TABLE 1 Primers used in this study
Primer Sequence (5= to 3=)
WT-F ATCGCTCGAGAAAAGAGCTGCAACACAT
WT-R CGATGAATTCTTACTTTATAGTTCCCCA
Chi1-F CAAAGAATGGTTAATTCATTTTCCCAATC
CACCGCTCAAGAC
Chi1-R GTCTTGAGCGGTGGATTGGGAAAATGAA
TTAACCATTCTTTG
Chi2-F CAAAGAATGGTCAACTCCTTCTCAAATT
CAACTGCCCAAGAT
Chi2-R ATCTTGGGCAGTTGAATTTGAGAAGGA
GTTGACCATTCTTTG
Chi3-F GAAGCTGGTTGGAGTAATTACGGAGGT
GGTAACCAAATCGGTTTGATC
Chi3-R GATCAAACCGATTTGGTTACCACCTCCG
TAATTACTCCAACCAGCTTC
Chi4-F GAGGCTGGTTGGTCCAACTACGGTGGA
GGTAATCAAATAGGTCTTATT
Chi4-R AATAAGACCTATTTGATTACCTCCACCG
TAGTTGGACCAACCAGCCTC
Chi5-F AAATATAATGTTAAAGTAGGAGATTACG
TCAAGGCTGGTCAAATCATC
Chi5-R GATGATTTGACCAGCCTTGACGTAATCT
CCTACTTTAACATTATATTT
Chi6-F AAGTACAACGTCAAGGTCGGTGACTAT
GTCAAAGCTGGTCAAATAATC
Chi6-R GATTATTTGACCAGCTTTGACATAGTCA
CCGACCTTGACGTTGTACTT
Chi7-F GGTCTTATTGAAAATGATGGAGTGCACA
GACAATGGTACATGCACTTG
Chi7-R CAAGTGCATGTACCATTGTCTGTGCACT
CCATCATTTTCAATAAGACC
Chi8-F GGTTTGATCGAGAACGACGGTGTCCATA
GACAATGGTATATGCATCTA
Chi8-R TAGATGCATATACCATTGTCTATGGACA
CCGTCGTTCTCGATCAAACC
Syn-F ATCGCTCGAGAAAAGAGCTGCTACCCAC
Syn-R CGATGAATTCTTACTTGATGGTACCCCA
N125Q-F AACTCCTTCTCCCAATCCACCGCTCAA
N125Q-R TTGAGCGGTGGATTGGGAGAAGGAGTT
N125D-F AACTCCTTCTCCGACTCCACCGCTCAA
N125D-R TTGAGCGGTGGAGTCGGAGAAGGAGTT
N125S-F AACTCCTTCTCCTCCTCCACCGCTCAA
N125S-R TTGAGCGGTGGAGGAGGAGAAGGAGTT
S126P-F AACTCCTTCTCCAACCCAACCGCTCAA
S126P-R TTGAGCGGTTGGGTTGGAGAAGGAGTT
T127A-F TTCTCCAACTCCGCTGCTCAAGACCCA
T127A-R TGGGTCTTGAGCAGCGGAGTTGGAGAA
Alfa-F ATGAGATTTCCTTCAATTTTTACTG
5Syn-R CACCGTCGTTCTCGATCAAACCGA
FullSyn-R CTTGATGGTACCCCACAAGACACC
5WT-R CTCCATCATTTTCAATAAGACCTA
FullWT-R CTTTATAGTTCCCCAAAGAACACC
AOX1-F ATTGCCGGAAGATTGGCAAACTTG
AOX1-R AAAACGATTTGCTTTCTAGCACGG
N125NNK-F AACTCCTTCTCCNNKTCCACCGCTCAA
N125NNK-R TTGAGCGGTGGAMNNGGAGAAGGAGTT
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extract, 2.0% peptone, 1.34% YNB, 0.00004% biotin, 1.0% glycerol, 100
mM phosphate buffer, pH 6.0), and finally induced in BMMY medium
(1.0% yeast extract, 2.0% peptone, 1.34% YNB, 0.00004% biotin, 0.5%
methanol, 100 mM phosphate buffer, pH 6.0). LST-expressing clones
were identified by SDS-PAGE analysis of culture supernatants.
RT-PCR. A 5= fragment or full-length LST mRNA was detected by
reverse transcription (RT)-PCR using forward primer WT-F or SYN-F
and reverse primer 5WT-R, 5SYN-R, FullWT-R, or FullSYN-R (Table 1).
As an internal positive control, a fragment of alcohol oxidase 1 (AOX1)
mRNA was detected with primers AOX1-F and AOX1-R.
Bioreactor culture. For pilot-scale production of LST, P. pastoris was
cultured in a 2-liter bioreactor as described previously (23). Briefly, a
3-stage fed-batch culture process was employed. First, P. pastoriswas cul-
tured at 30°C in 1.5 liters of low-salt BSM medium (per liter, 20 ml 85%
phosphoric acid, 0.2 g calcium sulfate, 5 g potassium sulfate, 4 g magne-
sium sulfate-7H2O, 1 g potassium hydroxide, 30 g glycerol). After the
initial glycerol had been exhausted, as identified by a dissolved oxygen
spike, the culture density was increased to an optical density at 600 nm
(OD600) of approximately 100 using a constant glycerol feed rate of 15
ml/h for 6 h. Finally, the culture temperature was decreased to 20°C and
the expression of lysostaphin was induced by a bolus injection of metha-
nol to a final concentration of 0.5%. A controlled methanol feed was
initiated upon full induction of the AOX1 promoter, indicated by a steady
decrease in dissolved oxygen concentration with the feeding of methanol.
A controlled dissolved oxygen (DO-stat) strategy was then employed to
maintain 20% dissolved oxygen by adjusting the methanol feed rate (24).
Lysostaphin purification. LST was precipitated from culture super-
natants by 25% polyethylene glycol (PEG) precipitation at room temper-
ature, resuspended in 20 mM NaHPO4 buffer, pH 7.5, and bound to a
HiPrep SP Sepharose fast flow 16/10 prepacked column that had been
equilibrated with the same buffer. Following a 10-column-volume wash
with the same buffer, LST was eluted with a 0-to-250 mMNaCl gradient,
occurring over 10 column volumes. The purity and concentration of
eluted LST was determined by SDS-PAGE gel densitometry, using a stan-
dard curve generated with commercially sourced LST.
MIC assay. The MIC of LST was determined by the microplate
method (25). Using 96-well polystyrene plates, 100-l aliquots of P. pas-
toris culture supernatant were serially diluted in tryptic soy broth (TSB),
while 100-l aliquots of purified LST were serially diluted in phosphate-
buffered saline (PBS; 2.7 mM KCl, 1.5 mM KH2PO4, 8.9 mM Na2HPO4,
136.9mMNaCl, pH7.4) supplementedwith 0.1%bovine serumalbumin.
Each well was then inoculated with 100 l of 	106 CFU/ml S. aureus
strain SA113 in TSB or Mueller-Hinton broth (BD) supplemented with
2%NaCl, yielding a total volume of 200l perwell.Microplates were then
incubated at 37°C for 24 h. The inhibitory activity in culture supernatants
was assessed as theMIC50, the treatment dilution yielding 50% inhibition
of growth. The inhibitory activity of purified LST was determined by the
MIC0, the enzyme concentration yielding complete inhibition of growth.
Both MIC0 and MIC50 were quantified by measuring light scattering at
650 nm in a microplate reader. All assays were performed in duplicate.
Turbidity assay. S. aureus strain SA113was cultured overnight inTSB,
pelleted by centrifugation, and washed once with PBS. The cells were then
resuspended in PBS, and this stock bacterial suspension was aliquoted
into replicate wells of a 96-well flat-bottomed polystyrene plate (Nunc
269620) (100l, A650
 0.8 in the plate). Lysis reactions were initiated by
adding purified LST to a final concentration of 5g/ml using a 12-channel
Pipetman. The kinetics of bacterial lysis were followed by measuring the
light scattering at 650 nm every minute for a total of 30 min. The activity
of the various LST constructs was defined as the time to reach half the
starting optical density (TOD50) of the initial bacterial suspension.
Thermostability assay.The relative thermostability of LST constructs
was determined by differential scanning fluorimetry on an Applied Bio-
systems ABI 7500 fast real-time PCR system, essentially as described pre-
viously (26). Proteins and SYPRO orange were diluted in PBS, and fluo-
rescence was quantified at 1-degree increments from 25 to 94°C.
PNGase F treatment.Onemicroliter of 10G7 reaction buffer and 1
l of Remove-iT PNGase Fwere added to 8l of culture supernatant. The
reactionmixture was incubated for 1 h at 37°C, and the reaction products
were analyzed by SDS-PAGE.
Saturationmutagenesis of LST residue 125. LST amino acid 125 was
subjected to saturation mutagenesis by splice overlap extension PCR us-
ing the SYN lst gene template and degenerate internal primers (NNK
codon, where N 
 A, G, C, or T and K 
 G or T) (Table 1). The 32-
member gene library was cloned and transformed into P. pastoris as de-
scribed above. Transformants were spread on YPM agar medium (1%
yeast extract, 2% peptone, 1%methanol, 1% agar) and incubated at 30°C
for 2 days. An overnight culture of S. aureus strain SA113 was diluted in
PBS to an OD600 of 1.0, and this bacterial suspension was mixed in a 1:10
ratiowithmolten top agar (0.5 yeast extract, 1%peptone, 1%NaCl, 0.75%
agar). The indicating top agar was poured onto the YPM yeast plates, and
the plates were incubated at 37°C for 10 h. Yeast clones expressing active
enzymes were identified by their characteristic halo or zone of clearance.
Halo-forming colonies were picked through the top agar, their cognate lst
genes were amplified with primers SYN-F and SYN-R (Table 1), and the
PCR products were sequenced.
Bioinformatics analysis. Sequence alignment was performed using
ClustalW (www.ebi.ac.uk/Tools/msa/clustalw2/). Codon analysis was
performed using CodonW (codonw.sourceforge.net). The frequency of
optimum codons (Fop) is defined by the formula (number of optimal
codons)/(total number of codons). Its values range from 0 (when a gene
contains no optimal codons) to 1 (when a gene is composed entirely of
optimal codons).
Gene sequence deposition. The optimized SYN lst gene sequence,
encoding the wild-type LST enzyme, has been deposited in GenBank with
the accession number KF724949.
RESULTS
Gene sequence optimization enables high-level expression of
LST in P. pastoris. In an effort to obtain high expression yields
from yeast, theWT lst genewas amplified from S. simulans, cloned
into P. pastoris expression vector pPIC9, and transformed into P.
pastoris strain GS115. This construct was devoid of the native LST
prepro sequence and was instead fused to the MF prepro se-
quence from S. cerevisiae. Following induction of the GS115 host,
however, no LST enzyme could be detected by SDS-PAGE analysis
of shake flask culture supernatants (Fig. 1A, WT lane).
Initial speculation tied the lack of any detectable expression to
differential codon bias in the bacterial gene versus the yeast host.
Specifically, the frequency of optimal P. pastoris codons (Fop)
within the WT lst gene is as low as 0.388. Moreover, a closer in-
spection of the WT lst gene revealed an extraordinarily high AT
content (62.6% overall). To address both putative issues simulta-
neously, an artificial gene (SYN lst) having an increased Fop of
0.978 and a decreased AT content of 47.3% was synthesized. In
contrast to WT lst, P. pastoris expression from the SYN lst gene
yielded substantial quantities of enzyme in the culture superna-
tant (	80 mg/liter in shake flask culture) (Fig. 1A, SYN lane).
Finemapping of problematic gene subsequences.To identify
specific regions of the WT lst gene that were responsible for poor
expression, a panel of chimeric WT-SYN genes was constructed
(Fig. 2A). While the complete lack of expression from WT lst
could not be traced to any single region of the gene, it was found
that detrimental sequences were not evenly distributed (Fig. 2B).
Importantly, the most critical determinant of poor expression
yields was confined to a 49-bp segment from nucleotide (nt) 228
to 276 (Chi8).
A detailed comparison of thisWT lst sub-sequence with that of
the SYN lst gene revealed that the key differenceswere thosewithin
Zhao et al.
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a narrow AT-rich region (from nt 252 to 267) (Fig. 1B). To
confirm the regulatory role of this 21-bp AT-rich region, the
corresponding sequence in the optimized SYN lst gene was re-
placed by the counterpart sequence from WT lst, yielding con-
struct SYNAT (Fig. 1B). Additionally, the same AT-rich seg-
ment of theWT lst gene was replaced with the corresponding SYN
lst sequence, thereby yielding construct WTAT, the inverse of
gene SYNAT. Analysis of culture supernatants by SDS-PAGE
revealed that replacement of the AT-rich region in WTAT
resulted in enhanced LST expression, albeit at lower levels than
fromSYN lst itself (Fig. 1A). In contrast, introduction of theAT-
rich region into the SYNAT construct did not reduce expression
compared to that of SYN lst.
Putative mechanism for compromised WT lst expression. It
was speculated that the AT-rich region was influencing expres-
sion by acting as a premature transcription terminator. To probe
this proposed mechanism, RT-PCR was used to detect mRNAs
corresponding to the full-length WT lst and SYN lst genes or
shorter 5= fragments thereof. Consistent with the hypothesis, ex-
pression levels were found to correlate well with the relative abun-
dance of mRNA. In particular, no LST-specific mRNA was de-
tected for theWT lst gene, a highmRNA level was detected for the
SYN lst gene, and a lowmRNA level was detected for theWTAT
construct (Fig. 1C).
Aberrant glycosylation of the WT LST protein. To evaluate
the potential of P. pastoris for pilot-scale production of LST, P.
pastoris encoding SYN lst was cultured in a 2-liter bioreactor. The
expression levels frombioreactor cultivationswere	500mg/liter,
and approximately 50% of this material could be recovered in
high purity by PEGprecipitation and cation exchange chromatog-
raphy.However, LST fromboth shake flask and bioreactor culture
migrated as doublets in SDS-PAGE (Fig. 3A, left). The two species
coeluted from cation exchange chromatography columns as a sin-
gle peak (Fig. 3B), and reducing themass of enzyme loaded on the
column did not increase chromatographic resolution (data not
FIG 1 Gene sequence optimization enables high-level expression of LST in P.
pastoris. (A) Comparison of LST expression levels from different recombinant
genes. Lanes: M, protein marker (top to bottom, 250, 150, 100, 75, 50, 37, 25,
and 20 kDa); WT, WT lst gene; SYN, SYN lst gene; SYNAT, the AT-rich
region (nt 252 to 267) from the WT lst gene was introduced into the SYN lst
gene; WTAT, the AT-rich region (nt 252 to 267) of the WT lst gene was
replaced by the corresponding sequence from the SYN lst gene. (B) Sequence
alignment of a region fromWT lst (nt 228 to 276) that caused the most signif-
icant decrease in expression when transplanted into the SYN lst gene. Asterisks
indicate nucleotides that are identical among all four gene sequences. Shaded
nucleotides are the six critical baseswhosemutationswere sufficient to activate
LST expression. (C) Full-length LST mRNA and a shorter 5= fragment were
detected by RT-PCR. A fragment of AOX1 mRNA was used as an internal
amplification and loading control. Lanes: M, DNA marker (top to bottom,
1,500, 1,000, 750, 500, and 250 bp); 1, fragment of AOX1; 2, 5= fragment of LST
mRNA; 3, full-length LST mRNA.
FIG 2 Mapping of dominant detrimental sequences in theWT lst gene. (A) Schematic representation of the chimeric genes examined (WT lst is in black and SYN
lst is in white). (B) Levels of LST expression from the panel of chimeric genes, as measured by quantitative densitometry of SDS-PAGE protein bands.
FIG 3 LST secreted from P. pastoris is aberrantly glycosylated. (A) LST from P.
pastoris culture supernatants migrates as a doublet (left), and treatment with
PNGase F eliminates the higher-molecular-mass upper band (right). Lanes:M,
proteinmarker (top to bottom, 250, 150, 100, 75, 50, 37, 25, and 20 kDa); 1, 10
l of supernatant of flask culture; 2, 10l of supernatant of bioreactor culture.
(B) Glycosylated and unglycosylated LST cannot be separated during cation
exchange chromatography. Lanes: M, protein marker (top to bottom, 250,
150, 100, 75, 50, 37, 25, and 20 kDa); 1 to 6, different fractions collected from
a single peak during chromatographic purification.
Aglycosylated Lysostaphin with Full Activity
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shown). The higher-molecular-mass material was thought to re-
sult from aberrant N-linked glycosylation, and indeed, the upper
banddisappeared fromSDS-PAGEafter PNGase F treatment (Fig.
3A, right). Consistent with prior observations that glycosylated
LST from mammalian cells is inactive (27), fast protein liquid
chromatography fractions containing higher proportions of gly-
cosylated LST (Fig. 3B, lanes 1 to 3) were less active in turbido-
metric assays (data not shown). Thus, there was a need to generate
aglycosylated variants to take full advantage of the P. pastoris ex-
pression host.
Construction and preliminary analysis of aglycosylated LST
variants. LST contains two consensus N-linked glycosylation se-
quons, one at position 125 (N125-S126-T127) and the other at
position 232 (N232-K233-T234). When the latter was disrupted
with an N232Q point mutation, the variant protein continued to
migrate as a doublet in SDS-PAGE (data not shown). This result
indicated that N125 was the site of aberrant glycosylation in P.
pastoris. Additional indirect evidence for this conclusion is also
provided by the recent demonstration that position N125 is the
site of glycosylation in mammalian cells (28). The N125 glycosy-
lation sequon was disrupted via a typical strategy wherein a con-
servative N¡Q, N¡D, or N¡S point mutation was introduced
at position 125. Each of these mutations successfully abolished P.
pastoris glycosylation of LST, and the expression yields of the three
variants were comparable to that of the wild-type protein (Fig.
4A). Surprisingly, however, MIC50 analysis of culture superna-
tants showed the aglycoslyated N125Q, N125S, and N125D
variants to exhibit approximately 10-, 20- and 40-fold-lower
activity levels, respectively, than native LST produced in P.
pastoris (Fig. 4B).
To comprehensively assess the functional plasticity of LST res-
idue 125, a small gene library was constructed by saturation mu-
tagenesis of the corresponding codon. Screening of approximately
300 transformants (representing 10-fold coverage of the library)
on indicating medium yielded only 4 active colonies able to gen-
erate halos (Fig. 5A). SDS-PAGE analysis showed that the LST
secreted from these 4 colonies migrated as doublets (Fig. 5B),
indicating that eachmutant encoded the native asparagine residue
at position 125. Further evidence of the strict requirement for an
asparagine at residue 125 was found by aligning the LST amino
acid sequence with those of two functional homologs (Ale-1 and
LytM) (Fig. 5C).
Given the unexpected and unfavorable outcome from the mu-
tation at position 125, two alternative aglycosylated variants, one
at position 126 (S126P) and one at position 127 (T127A), were
constructed, expressed, and analyzed. Similar to the results ofmu-
tations at N125, the LST(S126P) and LST(T127A) variants were
uniformly aglycosylated and were expressed at levels comparable
to the wild-type enzyme (Fig. 4A). Importantly, both of the new
variants possessed bactericidal activity equivalent to that of wild-
type LST (Fig. 4B).
Detailed analysis of highly active aglycosylated LST variants.
The two most highly active aglycosylated variants, LST(S126P)
and LST(T127A), were expressed in 2-liter bioreactors and puri-
fied to homogeneity following the same production process as for
wild-type LST (Fig. 6A). The expression levels and final purified
yields of both aglycosylated variants were similar to those of wild-
type LST. The activities and thermostabilities of aglycosylated LST
variants were compared with those of commercially sourced LST
as a reference. In kinetic turbidometric assays, the TOD50 values of
FIG 4 Expression of aglycosylated LST from P. pastoris. (A) Expression of aglycosylated LST variants. Lanes: M, protein marker (top to bottom, 250, 150, 100,
75, 50, 37, 25, and 20 kDa); 1, LST; 2, LST(N125Q); 3, LST(N125D); 4, LST(N125S); 5, LST(S126P); 6, LST(T127A). All variants exhibited similar expression
levels. (B) Activity assays of aglycosylated LST variants. MIC assays with S. aureus SA113 were performed on 2-fold serial dilutions of culture supernatants. The
OD650 readings for each enzyme dilution series are shown, and a dashed line indicates the reading corresponding to the MIC50. Error bars represent standard
deviations.
FIG 5 Asparagine at position 125 is essential for the full activity of LST. (A) An
LST saturation mutagenesis library at position 125 was screened by plate halo
assay, and all functional cloneswere picked for further analysis. (B) SDS-PAGE
analysis of LST secreted from the halo-forming colonies. Lanes: M, protein
marker (top to bottom, 250, 150, 100, 75, 50, 37, 25, and 20 kDa); 1st to 4th,
LST secreted from the halo-forming colonies; 5th, commercial LST purchased
from Sigma. (C) Sequence alignment of LST with two related staphylocidal
lysins (Ale-1 and LytM) shows that N125 is conserved in all three enzymes.
Asterisks indicate positions having one identical residue, colons indicate posi-
tions occupied by residues having strongly similar properties, periods indicate
positions occupied by residues having weakly similar properties, and gaps
indicate positions occupied by dissimilar residues.
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LST(S126P), LST(T127A), and commercial LST were 5, 7, and 17
min, respectively (Fig. 6B). In antibacterial assays against a small
panel of clinical isolates (strains 6445, 3425-1, and 3425-3) and a
laboratory strain (SA113), both variants exhibited MIC values
equivalent to those of the commercial enzyme (Fig. 6C). With
respect to structural stability, LST(S126P) showed a single appar-
ent melting temperature (Tm) of 57°C and LST(T127A) a single
Tm of 59°C (Fig. 6D). This is in contrast to commercially sourced
wild-type LST, which exhibited two distinct transitions, one at
47°C and another at 60°C.
DISCUSSION
Because of its lack of endotoxin and high inherent capacity for
recombinant protein expression and secretion, P. pastoris is be-
coming increasingly attractive as a cost-effective production plat-
form for therapeutic proteins. In some cases, however, biothera-
peutic protein expression levels have been found to be low to
undetectable (29). Protein secretion from P. pastoris is a multiple-
step process involving transcription, translation, protein folding,
and translocation through the secretory pathway. Any one of these
stepsmay be rate limiting for a given protein target (30, 31). Thus,
while P. pastoris has numerous advantages for biotherapeutic pro-
tein production, obtaining high levels of expression with recalci-
trant targets can be a difficult problem.
Gene sequence optimization has been a widely effective mea-
sure to increase heterologous protein expression levels in P. pas-
toris (32–36), but the mechanism behind this strategy has seldom
been studied. The results presented herein are consistent with
prior insights that premature transcription termination may re-
sult from short segments of severe nucleotide bias within some
native genes (37–39). Thus, targeted disruption of these regions
may represent an efficient and cost-effective strategy for gene op-
timization compared to the whole-gene synthesis strategy. In the
current study, the comparison of expression levels from the WT,
WTAT, SYN, and SYNAT constructs indicates that the core
21-bp AT-rich sequence is necessary but not sufficient for a
putative premature transcription termination signal. Notably, re-
placement of a mere six nucleotides was sufficient to activate ex-
pression from the otherwise incompetent WT lst gene.
Aberrant glycosylation is another frequently encountered bar-
rier to high levels of production of functional proteins from P.
pastoris. As shown here, this is indeed the case for the antibacterial
enzyme LST. In most instances, destruction of the glycosylation
sequon is accomplished by replacing the N-linked asparagine res-
idue with glutamine, aspartic acid, serine, or alanine (40–43). In
the current study of LST glycosylation, all mutations at the N-
linkedN125 residue led to significantly decreased enzyme activity,
whereas mutations at two adjacent residues (S126 and T127)
yielded fully functional aglycosylated variants. The severely com-
promised activity of the N125 mutants was especially surprising
FIG 6 Detailed analysis of aglycosylated LST variants. (A) SDS-PAGE analysis of enzyme expression and purification. Lanes: M, marker; 1, 10l of supernatant
from shake flask culture; 2, 10 l of supernatant from bioreactor culture; 3, 10 g of purified protein. (B) Kinetic analysis of S. aureus lysis in microplate
turbidometric assays. The horizontal line provides a visual guide to assess TOD50. (C) Antibacterial efficacy as measured by MIC assay. An S. aureus laboratory
strain (SA113) and three clinical isolates were assessed for growth inhibition by serial dilutions of purified enzymes. TheOD650 readings after 24 h of growth show
that, while the different strains exhibited different MIC0 values (P
 0.0008, two-way analysis of variance), wild-type LST and the engineered variants did not
exhibit significantly differentMIC0s for any given strain (P
 0.8281), andneitherwas there a significant interaction between the different enzyme treatments and
different strains (P 
 0.6529). (D) Melting temperature analysis by differential scanning fluorimetry. The engineered aglycoslyated variants exhibit a single
transition, whereas commercial wild-type LST exhibits two distinct transitions, one at a substantially lower temperature. Error bars represent standard deviations
from three experiments.
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given the fact that residue 125 is thought to be located at the
C-terminal end of the catalytic domain, and prior studies of key
LST catalytic residues did not identify N125 (2). Molecular mod-
eling of the LST catalytic domain suggested that substitutions at
position 125 caused minimal structural perturbation and affected
the peptide backbone even less than mutations at positions 126
and 127 (data not shown). Therefore, an understanding of the
strict requirement for an asparagine at position 125 awaits more-
specific and in-depthmechanistic and structural analyses. Regard-
less, the current study demonstrates an unexpected positional
constraint formutations able to disrupt anN-linked glycosylation
sequon while maintaining protein function.
It has been shown that transgenic animals expressing LST have
enhanced resistance to staphylococcal infections (44). However,
transgenic expression of the native LST enzyme is suboptimal, as
aberrant glycosylation was found to abolish its activity (27). To
address this issue, aglycosylated LST variants with decreased ac-
tivity (such as N125Q) have been used in transgenic animal pro-
duction (27, 45). Notably, only animals expressing the highest
LST(N125Q) levels were completely resistant to staphylococcal
infection.We speculate that the optimized aglycosylated LST vari-
ants described here would greatly enhance the utility of LST in
transgenic animals, and more generally, we anticipate that other
functionally sensitive proteins will benefit from a broadened
choice of mutations able to disrupt undesirable N-linked glycosy-
lation sequons.
In conclusion, an efficient high-level-production system has
been constructed for LST in the yeast host P. pastoris. By a com-
bination of gene sequence, protein sequence, and bioprocess op-
timization, expression levels of 500 mg/liter and final purified
yields of 250 mg/liter have been obtained in laboratory-scale bio-
reactors. These high yields and the ease of purification for the
secreted, endotoxin-free enzyme should facilitate future develop-
ment of LST applications, particularly those relating to treating
bacterial infections in mammals.
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